Home > Oncology > ESMO 2021 > Genitourinary Cancer > TKI drug-free interval strategy not detrimental to conventional continuation strategy in RCC

TKI drug-free interval strategy not detrimental to conventional continuation strategy in RCC

Presented By
Prof. Janet Brown, University of Sheffield, UK
Conference
ESMO 2021
Trial
Phase 2, STAR
First results from the phase 2/3 STAR trial showed that a drug-free interval strategy in tyrosine kinase inhibitor (TKI)-therapy in patients with advanced/metastatic renal cell carcinoma (RCC) is not detrimental to overall survival (OS) and quality of life compared with conventional continuation strategy, and has a significant cost saving effect. TKI therapy is an important backbone in the management of locally advanced or metastatic RCC, with significant survival advantage. However, TKI therapy is associated with significant toxicities which often lead to dose reduction and/or discontinuation of treatment. In addition, TKI therapy comes with high costs. The multicentre, randomised, phase 2/3 STAR trial (EudraCT 2011-001098-16) was designed to determine if a TKI drug-free interval strategy (DFIS) was non-inferior to a conventional con...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on